Vitamin D Deficiency among Patients with Tuberculosis: a Cross-Sectional Study in Iranian-Azari Population.
25-hydroxyvitamin D
Epidemiology
Mycobacterium Tuberculosis
Pulmonary
Vitamin D Deficiency
Journal
Tanaffos
ISSN: 1735-0344
Titre abrégé: Tanaffos
Pays: Iran
ID NLM: 101308232
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
entrez:
20
8
2019
pubmed:
20
8
2019
medline:
20
8
2019
Statut:
ppublish
Résumé
Vitamin D deficiency or insufficiency has been conducted with increased risk for tuberculosis (TB). Despite this association, discrepancies exist among different studies in different regions. The aim of this study was to evaluate the prevalence of vitamin D deficiency and its predictors in tuberculosis among the Iranian-Azari population. A total of 60 participants were enrolled in this study, 30 of which were newly diagnosed TB patients and 30 were healthy volunteers. At least two serum samples were collected, the first sample before the start of anti-TB treatment and the second sample 3 months after the effective treatment. The prevalence of vitamin D deficiency (25 patients vs. 2 healthy individuals; P<0.001) and serum levels of the vitamin D (22.66±15.17 vs. 73.03±25.6 ng/mL; P<0.001) were significantly higher in patients with TB than healthy subjects. Likewise, the prevalence of vitamin D deficiency in the extrapulmonary TB group was higher than that of the pulmonary TB, but this difference was not statistically significant (P=0 .397). Moreover, there was no significant difference between mean levels of vitamin D in patients with tuberculosis before and after treatment (P = 0.787). Linear regression analysis showed there was no significant relationship between vitamin D levels after treatment and age, gender, body site of tuberculosis, and vitamin D levels before treatment, P≥0.68. Vitamin D deficiency is higher in patients with tuberculosis than healthy individuals.
Sections du résumé
BACKGROUND
BACKGROUND
Vitamin D deficiency or insufficiency has been conducted with increased risk for tuberculosis (TB). Despite this association, discrepancies exist among different studies in different regions. The aim of this study was to evaluate the prevalence of vitamin D deficiency and its predictors in tuberculosis among the Iranian-Azari population.
MATERIALS AND METHODS
METHODS
A total of 60 participants were enrolled in this study, 30 of which were newly diagnosed TB patients and 30 were healthy volunteers. At least two serum samples were collected, the first sample before the start of anti-TB treatment and the second sample 3 months after the effective treatment.
RESULTS
RESULTS
The prevalence of vitamin D deficiency (25 patients vs. 2 healthy individuals; P<0.001) and serum levels of the vitamin D (22.66±15.17 vs. 73.03±25.6 ng/mL; P<0.001) were significantly higher in patients with TB than healthy subjects. Likewise, the prevalence of vitamin D deficiency in the extrapulmonary TB group was higher than that of the pulmonary TB, but this difference was not statistically significant (P=0 .397). Moreover, there was no significant difference between mean levels of vitamin D in patients with tuberculosis before and after treatment (P = 0.787). Linear regression analysis showed there was no significant relationship between vitamin D levels after treatment and age, gender, body site of tuberculosis, and vitamin D levels before treatment, P≥0.68.
CONCLUSION
CONCLUSIONS
Vitamin D deficiency is higher in patients with tuberculosis than healthy individuals.
Types de publication
Journal Article
Langues
eng
Pagination
11-17Déclaration de conflit d'intérêts
CONFLICTS OF INTERESTS There are no conflicts of interest.
Références
Lancet. 2000 Feb 19;355(9204):618-21
pubmed: 10696983
Calcif Tissue Int. 2000 Jun;66(6):476-8
pubmed: 10821887
J Clin Endocrinol Metab. 2001 Mar;86(3):1212-21
pubmed: 11238511
Public Health Rep. 2003 May-Jun;118(3):240-60
pubmed: 12766219
Monaldi Arch Chest Dis. 2008 Mar;69(1):24-31
pubmed: 18507196
Pediatr Infect Dis J. 2008 Oct;27(10):941-2
pubmed: 18776821
J Nutr. 2008 Dec;138(12):2474-80
pubmed: 19022975
J Clin Endocrinol Metab. 2010 Feb;95(2):471-8
pubmed: 20133466
Clin Biochem. 2010 Dec;43(18):1431-5
pubmed: 20875809
BMC Infect Dis. 2010 Oct 25;10:306
pubmed: 20973965
Lancet. 2011 Jan 15;377(9761):242-50
pubmed: 21215445
Sci Transl Med. 2011 Oct 12;3(104):104ra102
pubmed: 21998409
Dermatoendocrinol. 2011 Oct;3(4):220-9
pubmed: 22259647
Respirology. 2012 Jul;17(5):808-13
pubmed: 22449254
Respir Investig. 2012 Jun;50(2):40-5
pubmed: 22749249
BMC Res Notes. 2013 Jul 25;6:293
pubmed: 23886009
J Coll Physicians Surg Pak. 2013 Nov;23(10):780-3
pubmed: 24169384
Int J Tuberc Lung Dis. 2014 Jan;18(1):73-8
pubmed: 24365556
Lancet Glob Health. 2014 Dec;2(12):e710-6
pubmed: 25433626
Int J Tuberc Lung Dis. 2015 Jan;19(1):65-9
pubmed: 25519792
PLoS One. 2015 Mar 30;10(3):e0120963
pubmed: 25822900
PLoS One. 2015 Apr 13;10(4):e0124339
pubmed: 25875760
Thorax. 2015 Dec;70(12):1171-80
pubmed: 26400877
Clin Microbiol Rev. 2016 Apr;29(2):239-90
pubmed: 26912567
N Engl J Med. 2016 Apr 28;374(17):1695-6
pubmed: 27007809
Int J Tuberc Lung Dis. 2016 Mar;20(3):383-8
pubmed: 27046721
Tuberculosis (Edinb). 2016 May;98:86-91
pubmed: 27156622
Tanaffos. 2016;15(1):37-43
pubmed: 27403177
Eur Respir J. 2016 Nov;48(5):1507-1510
pubmed: 27799393
Drug Des Devel Ther. 2016 Dec 28;11:91-102
pubmed: 28096657
BMC Infect Dis. 2017 Apr 27;17(1):312
pubmed: 28449659
Tanaffos. 2016;15(4):197-204
pubmed: 28469675
Clin Ther. 2017 May;39(5):946-957
pubmed: 28476406
Ann Clin Microbiol Antimicrob. 2017 May 11;16(1):36
pubmed: 28490367
Clin Nutr. 2018 Jun;37(3):1034-1040
pubmed: 28514999
Tuberculosis (Edinb). 2017 Sep;106:62-72
pubmed: 28802407
J Clin Transl Endocrinol. 2014 Aug 23;1(4):167-169
pubmed: 29159097
Sci Rep. 2018 Jan 17;8(1):997
pubmed: 29343733